NASDAQ$ESPR
Esperion Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Esperion's Q3 2021 financial results were reported, highlighting strategic adjustments and progress in clinical trials.
Esperion reported U.S. net product revenue of $10.9 million for Q3 2021. The company is focusing on aligning its operational and expense structure for long-term growth, with the CLEAR Outcomes study on track for MACE accumulation in 2H 2022.
- Announced strategic plan to align operational and expense structure.
- Achieved 80% MACE accumulation in the CLEAR Outcomes Trial in October.
- Continued European rollout of NILEMDO® and NUSTENDI® with partner Daiichi Sankyo.
- Entered into an agreement to exchange $15 million of convertible notes for common stock.
Headline financials
Revenue & EPS history
Esperion · Revenue · Quarterly
$14.4M
Revenue by segment
Esperion · $14.4M total across 2 segments · Q3 2021
- U.S. Net Product Revenue$10.9M+230.2%75.6%
- Collaboration Revenue$3.51M+600.0%24.4%
Forward guidance
Esperion anticipates Research and Development expenses for fiscal year 2022 to be $100 to $110 million and Selling, General and Administrative expenses for fiscal year 2022 to be $120 to $130 million. Esperion expects fiscal year 2022 operating expenses to be $220 to $240 million, inclusive of $25 million of non-cash, stock-based compensation expense.
Tailwinds
- Research and Development expenses for the full year 2021 are expected to be $110 million to $115 million.
- Selling, General and Administrative expenses for the full year 2021 are expected to be $195 million to $200 million.
- Esperion expects full-year 2021 operating expenses to be approximately $305 million to $315 million, inclusive of $25 million of non-cash, stock-based compensation.
- Research and Development expenses for fiscal year 2022 to be $100 to $110 million
- Selling, General and Administrative expenses for fiscal year 2022 to be $120 to $130 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-2.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.9%
Avg return
30 days after
41%
18 / 44 earnings
Positive
+23.0%
Q3 2018
Best reaction
-47.6%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -0.6% | — | |
| Q4 2025 | -11.5% | -19.7% | -28.3% | |
| Q3 2025 | -15.0% | +5.4% | +26.9% | |
| Q1 2025 | -7.7% | -23.8% | +10.5% | |
| Q4 2024 | +12.0% | +7.0% | -18.4% | |
| Q3 2024 | +3.2% | +10.0% | +57.5% | |
| Q2 2024 | -10.9% | -3.0% | -13.9% | |
| Q1 2024 | -3.8% | +3.3% | +16.5% | |
| Q4 2023 | -2.3% | -3.0% | +1.9% | |
| Q3 2023 | +3.7% | -5.2% | +64.6% | |
| Q2 2023 | +14.0% | +3.8% | +1.9% | |
| Q1 2023 | +8.1% | +14.1% | +0.0% | |
| Q4 2022 | -3.9% | +4.7% | -73.6% | |
| Q3 2022 | -1.1% | +5.3% | -14.6% | |
| Q2 2022 | +5.9% | +11.9% | +41.1% | |
| Q1 2022 | +11.3% | -3.8% | -1.9% | |
| Q4 2021 | +5.5% | +9.1% | +32.8% | |
| Q3 2021 | +5.3% | +2.3% | -11.3% | |
| Q2 2021 | -6.6% | -5.2% | -12.7% | |
| Q1 2021 | -25.1% | -16.5% | -20.7% | |
| Q4 2020 | -0.2% | -4.2% | -1.9% | |
| Q3 2020 | -19.3% | -15.7% | -0.8% | |
| Q2 2020 | -11.9% | -13.7% | -0.1% | |
| Q1 2020 | +8.8% | +19.1% | +11.9% | |
| Q4 2019 | -11.5% | -5.4% | -38.1% | |
| Q3 2019 | -8.0% | -5.2% | +22.4% | |
| Q2 2019 | -2.0% | -2.3% | -9.6% | |
| Q1 2019 | +5.0% | +0.3% | +2.5% | |
| Q4 2018 | +1.2% | +0.7% | -14.1% | |
| Q3 2018 | +23.0% | +29.4% | +17.0% | |
| Q2 2018 | +3.2% | +4.2% | +10.6% | |
| Q1 2018 | -47.6% | -41.8% | -46.1% | |
| Q4 2017 | +1.2% | +5.3% | -6.1% | |
| Q3 2017 | -1.9% | +0.0% | +12.7% | |
| Q2 2017 | +11.9% | +9.2% | +10.4% | |
| Q3 2016 | -2.5% | -3.9% | +8.8% | |
| Q2 2016 | -1.0% | -2.2% | -4.2% | |
| Q1 2016 | -7.8% | — | — | |
| Q4 2015 | -3.4% | — | — | |
| Q3 2015 | -3.3% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +2.6% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro